The earnings call reflects a positive sentiment with record revenue and significant growth in test volumes and revenue per territory. Strategic expansions in sales and leadership, along with successful biomarker launches, highlight strong operational progress. However, increased operating expenses and net losses present challenges to profitability, balancing some of the positive momentum.

Company Guidance -

Q3 2025

During the Exagen Inc. Q2 2025 earnings call, the company reported record revenue of $17.2 million, marking a 14% year-over-year growth. The AVISE CTD test volume also significantly increased, contributing to an average revenue per territory of over $430,000, up from $285,000 a few years ago. The company's trailing 12-month AVISE CTD average selling price (ASP) grew by $27 to $428, driven primarily by new biomarkers. Gross margin was slightly over 60%, with operating expenses at $13 million. Exagen ended the quarter with $30 million in cash and equivalents, maintaining a path to neutral operating cash flow. The company provided a full-year revenue guidance range of $65 million to $70 million, with expectations of achieving positive adjusted EBITDA by Q4 2025.

Record Revenue Achieved

Q2 revenue reached $17.2 million, marking a 14% year-over-year growth and the highest quarterly revenue in company history.

Significant AVISE CTD Test Volume Growth

The AVISE CTD test volume showed substantial growth, achieving the best quarterly volume since strategic adjustments in 2023.

Increased Revenue Per Territory

Average revenue per territory increased to over $430,000 for the quarter, a 50% growth since the CEO joined, showing strong commercial leverage.

Successful Biomarker Launch

The new T cell and RA markers launched in January continue to be a catalyst in commercial discussions, with positive clinical impacts reported.

Strategic Leadership Additions

Dr. Michael Mahler joined as Chief Scientific Officer, bringing significant R&D experience, and Chas McKhann joined the Board of Directors, enhancing strategic oversight.

Strong Financial Position

Exagen ended the quarter with over $30 million in cash and equivalents and is approaching neutral operating cash flow.

Expansion of Sales Territories

The sales force expanded from 40 to 42 territories, with plans to grow further, indicating a commitment to market penetration and growth.

Exagen (XGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.16 / -	-0.28	―	―	―
Jul 29, 2025	2025 (Q2)	-0.15 / -0.21	-0.16	-31.25% (-0.05)	―
May 05, 2025	2025 (Q1)	-0.20 / -0.20	-0.19	-5.26% (-0.01)	―
Mar 11, 2025	2024 (Q4)	-0.26 / -0.20	-0.31	35.48% (+0.11)	―
Nov 12, 2024	2024 (Q3)	-0.29 / -0.28	-0.31	9.68% (+0.03)	―
Aug 05, 2024	2024 (Q2)	-0.34 / -0.16	-0.28	42.86% (+0.12)	―
May 13, 2024	2024 (Q1)	-0.36 / -0.19	-0.44	56.82% (+0.25)	―
Mar 18, 2024	2023 (Q4)	-0.43 / -0.31	-0.83	62.65% (+0.52)	―
Nov 13, 2023	2023 (Q3)	-0.47 / -0.31	-0.47	34.04% (+0.16)	―
Aug 07, 2023	2023 (Q2)	-0.50 / -0.28	-0.78	64.10% (+0.50)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$7.39	$8.45	+14.34%
May 05, 2025	$6.02	$6.25	+3.82%
Mar 11, 2025	$2.85	$3.37	+18.25%
Nov 12, 2024	$2.97	$2.79	-6.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exagen Inc (XGN) report earnings?

Exagen Inc (XGN) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Exagen Inc (XGN) earnings time?

Exagen Inc (XGN) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XGN EPS forecast?

XGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing